Get the Stockscreener App
0.601
0.17%
-0.001
After Hours:
.60
-0.001
-0.17%
Barinthus Biotherapeutics Plc Adr stock is traded at $0.601, with a volume of 19,734.
It is down -0.17% in the last 24 hours and down -14.14% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
See More
Previous Close:
$0.602
Open:
$0.6
24h Volume:
19,734
Relative Volume:
0.62
Market Cap:
$24.55M
Revenue:
$15.12M
Net Income/Loss:
$-52.48M
P/E Ratio:
-0.465
EPS:
-1.2924
Net Cash Flow:
$-36.52M
1W Performance:
-2.59%
1M Performance:
-14.14%
6M Performance:
-18.56%
1Y Performance:
-66.42%
1-Day Range:
$0.60
$0.6075
1-Week Range:
$0.60
$0.6548
52-Week Range:
$0.512
$1.83
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
20400 CENTURY BLVD, GERMANTOWN
Compare BRNS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
0.601 | 24.59M | 15.12M | -52.48M | -36.52M | -1.2924 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | Morgan Stanley | Overweight |
| May-25-21 | Initiated | William Blair | Outperform |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
Barinthus Biotherapeutics plc Sponsored ADR Revenue Breakdown – GETTEX:2AB - TradingView
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Price to sales forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB - TradingView
Enterprise value to revenue forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB - TradingView
Price to earnings forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB - TradingView
2AB Forecast — Price Target — Prediction for 2027 - TradingView
Burke & Herbert (BHRB) Upgraded to Buy: Here's Why - Yahoo Finance
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy - Yahoo Finance
Bayer (BAYRY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BeOne Medicines Ltd.Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Bain Capital Specialty (BCSF) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BRNSBarinthus Biotherapeutics Plc ADR Stock Price and Quote - Finviz
Barinthus Biotherapeutics shareholders approve scheme of arrangement - Investing.com
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? - Morningstar
USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Barinthus Biotherapeutics (NASDAQ: BRNS) cuts Q1 loss while pursuing Clywedog merger - Stock Titan
What Makes Haleon PLC Sponsored ADR (HLN) a New Buy Stock - Yahoo Finance
Why Brainsway (BWAY) Might be Well Poised for a Surge - Yahoo Finance
ProShares Russell 2000 Dividend Growers ETF $SMDV Shares Sold by Capital Investment Advisors LLC - Defense World
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy - Yahoo Finance
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - Finviz
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance
Haleon PLC Sponsored ADR (HLN) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Banco Santander-Brazil (BSBR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Large Increase in Short Interest - Defense World
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Lowe’s Companies, Inc. $LOW Shares Acquired by Arbor Investment Advisors LLC - Defense World
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Should I buy Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) - Zacks Investment Research
Barinthus Bio reports positive initial data from celiac therapy trial - Investing.com
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Barinthus Bio joins forces with metabolic disease biotech in reverse merger - Fierce Biotech
Liminatus Pharma (LIMN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Surging Earnings Estimates Signal Upside for Brainsway (BWAY) Stock - Yahoo Finance
Europe Shingles Vaccine Market Size & Outlook, 2025-2030 - Grand View Research
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Improved Revenues Required Before Barinthus Biotherapeutics plc (NASDAQ:BRNS) Stock's 29% Jump Looks Justified - Sahm
Mexico Shingles Vaccine Market Size & Outlook, 2025-2030 - Grand View Research
Asia Pacific Shingles Vaccine Market Size & Outlook, 2030 - Grand View Research
North America Shingles Vaccine Market Size & Outlook, 2030 - Grand View Research
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):